In addition to the underwhelming response of BRAFV600E CRC to selective BRAF inhibition, such inhibitors are contraindicated in KRASWT/BRAFWT and KRASmut/BRAFWT backgrounds due to the RAS-mediated paradoxical activation of MAPK [38]. The gene discussed is BRAF; the disease is colorectal carcinoma.